Drugs Xagena
The ASCO Task Force has applied the Framework to four clinical scenarios in which multiple trials have compared new treatment options with current standards of care: first-line treatment for metastati ...
The European Commission has granted approval for the use of ALIMTA ( Pemetrexed for injection ) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer ...
The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab), an anti-PD-1 ( programmed death receptor-1 ) therapy, for the first-line treatment of patients with metastatic non-smal ...
The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line treatment of metastatic no ...
The FDA ( U.S. Food and Drug Administration ) has granted approval for a new indication for Alimta ( Pemetrexed for injection ) in combination with Pembrolizumab ( Keytruda ) and Platinum chemotherapy ...
The European Commission has approved Keytruda ( Pembrolizumab ), anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line treatment of metastatic nonsq ...
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with chemotherapy ( Abraxane [ Paclitaxel protein-bound; nab-Paclitaxel ] and Carboplatin ) for the i ...
Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was approved by the U.S. Food and Drug Administration ( FDA ) for the first-line treatment of adult p ...
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) as a first-line treatment for adults with metastatic non-small cell lung cancer ( NSCLC ) whose tumours have high PD ...
The U.S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ) 360 mg every three weeks plus Yervoy ( Ipilimumab ) 1 mg/kg every six weeks ( injections for intravenous use ) for the f ...
The European Commission ( EC ) has approved Opdivo ( Nivolumab ) plus Yervoy ( Ipilimumab ) with two cycles of Platinum-based chemotherapy for the first-line treatment of adult patients with metastati ...
European Commission has approved Tecentriq ( Atezolizumab ) as a first-line treatment for adults with metastatic non-small cell lung cancer ( NSCLC ) whose tumours have high PD-L1 expression, with no ...
